HUDDINGE, Sweden–(BUSINESS WIRE)–Regulatory News:
Medivir AB (STO:MVIR-B) announced that MIV-802 has been selected as a
candidate drug (CD) from its hepatitis C virus (HCV) nucleotide
polymerase inhibitor project for the treatment of HCV infection, and is
entering non-clinical development.
Approximately 120 million people are chronically infected with HCV
globally*. HCV causes progressive liver disease in many of those who are
chronically infected, and this can lead ultimately to cirrhosis,
hepatocellular carcinoma and a requirement for liver transplantation.
However the infection is curable with combinations of antiviral agents,
and nucleotide inhibitors of the viral polymerase have been shown to be
central to many of the most effective drug combinations for treating HCV.
MIV-802 is a highly potent and selective nucleotide inhibitor of the
replication of all genotypes of the hepatitis C virus in antiviral
assays. Preclinical data indicate that it can be used effectively in
combination with other classes of antiviral agents used to treat HCV,
including protease inhibitors and NS5A inhibitors. MIV-802 has been
designed to deliver large amounts of the drug selectively to the liver,
where the hepatitis C virus replicates. Medivir expects to communicate
the preclinical antiviral and pharmacokinetic profile of MIV-802 at a
major scientific meeting in 2015.